Prospective Tumor Response Evaluation
| Status: | Terminated |
|---|---|
| Conditions: | Liver Cancer, Liver Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 10/20/2018 |
| Start Date: | January 2016 |
| End Date: | April 2017 |
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies
The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and
metabolomic characteristics of liver tumors. The study also aims to determine if these
imaging characteristics are correlated with clinical outcomes.
metabolomic characteristics of liver tumors. The study also aims to determine if these
imaging characteristics are correlated with clinical outcomes.
For each treatment arm, pre-procedural MRI and post procedural MRI will be obtained.
Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression,
proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging
characteristics from tumors will be extracted using automated software—the study will apply a
computational analysis system with the capability to extract and analyze imaging
characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor
characteristics. Imaging findings will be correlated to clinical outcomes and genetic,
proteomic, and metabolomic findings to determine association. Imaging findings and genomic,
proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes
(time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).
Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression,
proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging
characteristics from tumors will be extracted using automated software—the study will apply a
computational analysis system with the capability to extract and analyze imaging
characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor
characteristics. Imaging findings will be correlated to clinical outcomes and genetic,
proteomic, and metabolomic findings to determine association. Imaging findings and genomic,
proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes
(time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).
Inclusion Criteria:
- Diagnosis or suspicion of primary or metastatic liver cancer deemed eligible for TACE,
Y-90, percutaneous ablation, and /or electroporation.
Exclusion Criteria:
- Any reason MRI cannot be obtained.
We found this trial at
1
site
7000 Fannin St
Houston, Texas 77030
Houston, Texas 77030
(713) 500-4472
University of Texas Health Science Center at Houston The University of Texas Health Science Center...
Click here to add this to my saved trials
